Akademik Veri Yönetim Sistemi
TuPA International Proteomics Congress 7 Turkish National Proteomics Congress, İstanbul, Türkiye, 18 - 19 Eylül 2025, ss.37, (Özet Bildiri)
Background: Bladder cancer(BC) ranks among the ten most common cancers, with 573,278 new cases reported worldwide. Novel early-stage diagnostic markers are needed to the detection of recurrence in patients. Serum biomarkers represent a promising approach for early-stage cancer diagnosis due to their non-invasive nature, high accuracy, and low cost. This study aimed to investigate the serum metabolomic profiles of NMIBC patients and healthy controls to identify potential candidate biomarkers. Method: 90 serum samples (n=54 cancer, n=36 control) were analyzed using a Orbitrap Exploris 240 High Resolution LC/MS(Thermo Scientific). Statistical analysis of the metabolites were performed using Compound Discoverer 3.3 SP1(Thermo Scientific) and MetaboAnalyst 6.0. Volcano plot analysis, PCA(principal component analysis) analysis and orthogonal partial least squares discriminant analysis(OPLS-DA) model were employed to distinguish between NMIBC patients and controls. For pathway analysis, KEGG metabolic pathway database was used. Findings: To investigate potential changes in serum metabolic profile associated with cancer, NMIBC patients were compared to controls. The significantly upregulated metabolites in the bladder cancer group (log2FC>1.5, p<0.05) include Phosphatidylcholine, 1-Acyl-sn-glycero-3-phosphocholine, Choline, Acetylcholine, Sphinganine, Sphingomyelin, Pantothenate, L-Valine, Uracil, Spermidine, 4-Guanidinobutanoate, Hydroxyproline, L-Proline, Uridine, 5-Oxoproline, and Spermidine. The identified metabolites were associated with key metabolic pathways, including arachidonic acid, linoleic acid, alpha-linolenic acid, glycerophospholipid, sphingolipid metabolisms, pantothenate and CoA biosynthesis, arginine and proline metabolism, pyrimidine metabolism, and glutathione metabolism. Conclusion: This study is one of the few to use untargeted UHPLC-MS specifically in early-stage BC patients to investigate serum metabolic alterations. Our findings are consistent with Zhao et al., who identified specific metabolites for distinguishing NMIBC, and with Guo et al., who reported altered pyrimidine metabolism in NMIBC. Our study suggest that specific metabolites are differentially expressed in NMIBC patients compared to healthy controls, indicating their potential as early-stage biomarkers. However, further validation studies are required to confirm their usability as potential biomarkers. Keywords: NMIBC, UHPLC-MS, serum, metabolomics, biomarkers